Advertisement

Summary and Review of the Abstracts on Philadelphia-Negative Myeloproliferative Neoplasms Presented at Haematocon 2017

  • Tathagata Chatterjee
  • Ankur Ahuja
Short Communication

Abstract

There are lot of grey zones in Philadelphia negative chronic myeloproliferative neoplasms (CMPNs) and that’s the reason they are in hit list of researchers. Having a spectrum of disorders their diagnosis is very important and especially to differentiate from each other since they overlap with each other in many ways. Diagnosis doesn’t start from lab but with clinical phenotype. Clinical phenotype not only able to provide us the diagnosis but also helps in management of the disease per se. When diagnosis comes, the old timer but an evergreen morphology plays an important role which along with the newer generation tool “molecular” helps in differentiating these disorders. Lot of studies have already come up from the world. Indian data has also started coming up. When we say about the Indian data nothing holds more important role than Indian Society of Haematology and Blood Transfusion, ISHBT. This small review will cover all papers with BCR-ABL negative CMPNs which were presented at the annual national conference of the ISHBT (Haematocon 2017) which was conducted at Guwahati. These abstract papers from various reputed institutes and centres will provide a short academic journey towards ongoing research activities at these places and will able to guide us regarding Philadelphia negative CMPNs and also stimulate our brain for some left or conflicted areas.

Keywords

Chronic myeloproliferative neoplasm Philadelphia negative Thrombophilia in CMPN Megakaryocyte morphology in CMPN JAK 2 mutation in CMPN 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical Approval

Not sought/required as this review article does not contain any studies with human participants performed by any of the authors.

References

  1. 1.
    Hammond E, Shaw K, Carnley B, P’ng S, James I, Herrmann R (2007) Quantitative determination of JAK2 V617F by TaqMan: an absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders. J Mol Diagn 9:242–248CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL (2010) Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. J Mol Diagn 12:58–64CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Denys B, El Housni H, Nollet F, Verhasselt B, Philippé J (2010) A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide. J Mol Diagn 12:512–519CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC (2007) The JAK2 V617F allele burden in essential thrombocythemia, polycythemiavera and primary myelofibrosiseimpact on disease phenotype. Eur J Haematol 79:508–515CrossRefPubMedGoogle Scholar
  5. 5.
    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061 (Erratum appeared in Lancet 2005, 366: 122) CrossRefPubMedGoogle Scholar
  6. 6.
    McClure R, Mai M, Lasho T (2006) Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 20:168–171CrossRefPubMedGoogle Scholar
  7. 7.
    Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168CrossRefPubMedGoogle Scholar
  8. 8.
    Cankovic M, Whiteley L, Hawley RC, Zarbo RJ, Chitale D (2009) Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods. Am J Clin Pathol 132:713–721CrossRefPubMedGoogle Scholar
  9. 9.
    Carillo S, Henry L, Lippert E, Girodon F, Guiraud I, Richard C, Dubois Galopin F, Cleyrat C, Jourdan E, Kralovics R, Hermouet S, Lavabre-Bertrand T (2011) Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations-clinical relevance in the monitoring of polycythemia. J Mol Diagn 13:263–270CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Murugesan G, Aboudola S, Szpurka H, Verbic MA, Maciejewski JP, Tubbs RR, Hsi ED (2006) Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 125:625–633CrossRefPubMedGoogle Scholar
  11. 11.
    Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP (2005) JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106:3370–3373CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Shepard GC, Lawson HL, Hawkins GA, Owen J (2011) BsaXI/RFLP analysis of initial or selectively reamplified PCR product is unreliable in detecting the V617F mutation in JAK2. Int J Lab Hematol 33:267–271CrossRefPubMedGoogle Scholar
  13. 13.
    Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D’Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemiavera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397CrossRefPubMedGoogle Scholar
  14. 14.
    Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) Again-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790CrossRefPubMedGoogle Scholar
  15. 15.
    James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148CrossRefPubMedGoogle Scholar
  16. 16.
    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061 (Erratum in Lancet 2005, 366: 122) CrossRefPubMedGoogle Scholar
  17. 17.
    Furtado LV, Weigelin HC, Elenitoba-Johnson KSJ, Betz BL (2013) Detection of MPL mutations by a novel allele-specific PCR-based strategy. J Mol Diagn 15(6):810–818CrossRefPubMedGoogle Scholar
  18. 18.
    Thangavelu H, Kumar AA, Kulkarni U, Devasia A, Korula A, Nisham PN et al (2017) Comparison of direct sequencing and allele specific PCR assay for detection of MPL mutations in essential thrombocythemia and primary myelofibrosis patients. Indian J Hematol Blood Transfus 33(Suppl 1):S1–S126Google Scholar
  19. 19.
    Pati HP, Sharma P (2016) Myeloproliferative neoplasms, an acquired thrombophilic state: JAK2 and beyond. Indian J Hematol Blood Transfus 32(3):245–247CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128:275–290CrossRefPubMedGoogle Scholar
  21. 21.
    Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120:5128–5133CrossRefPubMedGoogle Scholar
  22. 22.
    Borowczyk M, Wojtaszewska M, Lewandowski K, Gil L, Lewandowska M, Lehmann-Kopydłowska A, Kroll-Balcerzak R, Balcerzak A, Iwoła M, Michalak M, Komarnicki M (2015) The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb Res 135:272–280CrossRefPubMedGoogle Scholar
  23. 23.
    Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, Rosing J, Ten Cate H, Falanga A (2008) Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 112:4061–4068CrossRefPubMedGoogle Scholar
  24. 24.
    Barbui T, Finazzi G, Falanga A (2013) Myeloproliferative neoplasms and thrombosis. Blood 122:2176–2184CrossRefPubMedGoogle Scholar
  25. 25.
    Falanga A, Marchetti M (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Program 2012:571–581Google Scholar
  26. 26.
    Singh K, Sazawal S, Sharma A, Chikkara S, Chaubey R, Kishor K, Mahapatra M, Saxena R Impact of combined JAK2 V617F mutation and the inherited thrombophilic factors on thrombotic risk in CMPNs: AIIMS experience. ISHBT Guwahati 2017Google Scholar
  27. 27.
    Zhao S, Zhang X, Xu Y, Feng Y, Sheng W, Cen J, Wu D, Han Y (2016) Impact of JAK2 V617F mutation burden on disease phenotype in Chinese patients with JAK2 V617F-positive polycythemia vera (PV) and essential thrombocythemia (ET). Int J Med Sci 13:85–89CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Sazawal S, Singh K, Chikkara S, Kumar D, Chaubey R, Mahapatra M (2017) Saxena R Influence of JAK2 V617F allele burden on clinical phenotype of polycythemia vera patients: AIIMS experience. ISHBT, GuwahatiGoogle Scholar
  29. 29.
    Vannucchi AM, Pieri L, Guglielmelli P (2011) JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Ther Adv Hematol. 2(1):21–32CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Tahlan A, Yadav S, Palta A (2017) Clinico-pathological spectrum of myeloneoproliferative neoplasm. Government Medical College & Hospital, Chandigarh, ISHBT, GuwahatiGoogle Scholar
  31. 31.
    Tanya, Basu D, Kar R (2017) Pathological spectrum of myeloproliferative neoplasm. Megakaryocyte morphology and morphometry in philadelphia negative myeloproliferative neoplasms—JIPMER experience, ISHBT, GuwahatiGoogle Scholar
  32. 32.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C (2014) Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F. Arch Pathol Lab Med 138:1203–1209CrossRefPubMedGoogle Scholar
  33. 33.
    Thiele J, Funke S, Holgado S, Choritz H, Georgii A (1984) Megakaryopoiesis in chronic myeloproliferative diseases: a morphometric evaluation with special emphasis on primary thrombocythemia. Anal Quant Cytol 6(3):155–167PubMedGoogle Scholar
  34. 34.
    Thiele J, Schneider G, Hoeppner B, Wienhold S, Zankovich R, Fischer R (1988) Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis–features of significance for the diagnosis of primary (essential) thrombocythaemia. Virchows Arch A Pathol Anat Histopathol 413(5):407–417CrossRefPubMedGoogle Scholar
  35. 35.
    Gianelli U, Iurlo A, Vener C et al (2008) The significance of bone marrow biopsy and JAK2 V617F mutation in the differential diagnosis between the ‘‘early’’ prepolycythemic phase of polycythemiavera and essential thrombocythemia. Am J Clin Pathol 130(3):336–342CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  1. 1.Army Hospital (Research and Referral)New DelhiIndia

Personalised recommendations